Achilles Therapeutics plc
NASDAQ Global SelectTotal Valuation
Achilles Therapeutics plc carries a market capitalization of 60.83M, placing it among publicly traded companies globally. Its enterprise value stands at -41.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 60.83M |
| Enterprise Value | -41.27M |
Share Statistics
Achilles Therapeutics plc currently has 41.09M shares outstanding.
| Shares Outstanding | 41.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.13 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | -1.33 |
| P/OCF Ratio | -1.30 |
Financial Position
Achilles Therapeutics plc maintains a current ratio of 6.04, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.04 |
| Quick Ratio | 5.84 |
| Debt / Equity | 3.51 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -44.88 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 485,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Achilles Therapeutics plc's stock has gained approximately 89.04075% over the past 52 weeks. The 50-day moving average sits at 1.33, while the 200-day moving average is 1.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | 89.04075% |
| 50-Day Moving Average | 1.33 |
| 200-Day Moving Average | 1.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -69.70M, while operating income came in at -72.03M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -72.03M |
| Pretax Income | -66.39M |
| Net Income | -66.88M |
| EBITDA | -69.70M |
| EBIT | -72.03M |
| Earnings Per Share (EPS) | -1.66 |
Balance Sheet
Achilles Therapeutics plc holds 86.05M in cash and equivalents against 3.62M in total debt, resulting in a net debt position of -86.05M. Total book value stands at -308.15M, with working capital of 93.16M providing operational flexibility.
| Cash & Cash Equivalents | 86.05M |
| Total Debt | 3.62M |
| Net Debt | -86.05M |
| Equity (Book Value) | -308.15M |
| Book Value Per Share | -7.64 |
| Working Capital | 93.16M |
Cash Flow
Achilles Therapeutics plc produced -31.69M in operating cash flow over the past twelve months. After subtracting -741,000.00 in capital expenditures, free cash flow totaled -32.43M - equivalent to -0.80 per share.
| Operating Cash Flow | -31.69M |
| Capital Expenditures | -741,000.00 |
| Free Cash Flow | -32.43M |
| FCF Per Share | -0.80 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.01 |
| FCF Yield | -75.20 |
Scores
Achilles Therapeutics plc posts an Altman Z-Score of -3.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.28 |